Abstract: This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CCR5 receptior. In addition, this invention relates to the treatment and prevention of disease states mediatd by CCR5.

Abstract: Compounds of the formula (I): are vitronectin receptor antagonists useful in the treatment of osteoporosis.

Abstract: Alpha-adrenergic receptor antagonsists having the formula (I) as set forth below which are useful to produce alpha-adrenergic antagonism, pharmaceutical compositions thereof, and methods of treatment therewith are disclosed: ##STR1## The variables X, R, Y, Het and A are as defined in the specification.

Abstract: Alpha-adrenoceptor antagonists having the formula: ##STR1## which are useful to produce .alpha.-adrenoceptor antagonism, pharmaceutical compositions including these antagonists, and methods of using these antagonists to produce .alpha.-adrenoceptor antagonism in mammals.

Abstract: Alpha-adrenoceptor antagonists having the formula: ##STR1## which are useful to produce .alpha.-adrenoceptor antagonism, pharmaceutical compositions including these antagonists, and methods of using these antagonists to produce .alpha.-adrenoceptor antagonism in mammals.

Abstract: This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Abstract: This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Abstract: The compounds represented by the formula (I) ##STR1## wherein n is 1 or 2; m is 0, 1 or 2; p is 9, 10, 11, 12 or 13; X is hydrogen or hydroxyl; R is hydroxyl or amino; R.sub.1 is hydrogen, amino or ##STR2## and R.sub.2 is hydroxyl, amino, ##STR3## with the proviso that when m is 0, R.sub.1 is hydrogen or pharmaceutically acceptable salts thereof have been found to be leukotriene antagonists and useful in the treatment of diseases in which leukotrienes are a factor, such as asthma.

Abstract: The compounds represented by the formula (I) ##STR1## wherein m is 0, 1 or 2; p is 9, 10, 11, 12 or 13; R.sub.1 is hydrogen, amino or ##STR2## R.sub.2 is hydroxyl, amino, --NHCH.sub.2 CO.sub.2 H, ##STR3## or --NHCH.sub.2 CONH.sub.2 ; and X is --CO.sub.2 H, --CH.sub.2 OH or ##STR4## with the proviso that when m is 0, R.sub.1 is hydrogen, or a pharmaceutically acceptable salt thereof have been found to be leukotriene antagonists and useful in the treatment of diseases in which leukotrienes are a factor, such as asthma.

Abstract: The compounds represented by the formula (I) ##STR1## wherein m is 0, 1 or 2; p is 9, 10, 11, 12 or 13; R.sub.1 ' is hydrogen, ##STR2## and R.sub.2 ' is amino, --NHCH.sub.2 CO.sub.2 R.sub.3 ', ##STR3## --NHCH.sub.2 CONH.sub.2 or --OR.sub.3 ' wherein R.sub.3 ' is an alkyl radical containing one to six carbon atoms with the proviso that when m is 0, R.sub.1 ' is hydrogen are chemical intermediates in the synthesis of leukotriene antagonists of the formula (II) ##STR4## wherein m and p, are described above and R.sub.1 is hydrogen, amino or ##STR5## R.sub.2 is hydroxyl, amino, --NHCH.sub.2 CO.sub.2 H, ##STR6## --NHCH.sub.2 CONH.sub.2 ; and X is ##STR7## --CO.sub.2 H or --CH.sub.2 OH which are useful in the treatment of diseases in which leukotrienes are a factor, such as asthma.